



## PRIOR AUTHORIZATION POLICY

- POLICY:** Transplantation – Grafapex Prior Authorization Policy
- Grafapex™ (treosulfan intravenous infusion – Medexus)

**REVIEW DATE:** 02/26/2025

---

### OVERVIEW

Grafapex, an alkylating drug, is indicated for use in combination with fludarabine as a preparatory regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients  $\geq 1$  year of age for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).<sup>1</sup>

### Disease Overview

Allogeneic HSCT has a vital role in the management of patients with various hematologic malignancies.<sup>2</sup> In patients undergoing allogeneic HSCT, conditioning regimens are given to eradicate malignant cells in the bone marrow (if utilizing a myeloablative regimen) and to immunosuppress the recipient to promote engraftment of healthy donor cells. It is estimated that over 8,000 allogeneic transplants were performed in the US in 2021. Common malignancies treated in this manner include AML and MDS. Allogeneic HSCT is done to replace the malignant hematopoietic cells with those derived from a healthy donor.

### Guidelines

The National Comprehensive Cancer Network (NCCN) guidelines for hematopoietic cell transplantation (version 2.024 – August 30, 2024) have not addressed Grafapex.<sup>2</sup> The NCCN guidelines recommended various conditioning regimens utilized in patients undergoing allogeneic HSCT, including busulfan and fludarabine. These agents have been used together, along with other agents (e.g., cyclophosphamide, thiotepa, clofarabine).

### Safety

Grafapex has a Boxed Warning regarding myelosuppression.<sup>1</sup>

### POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Grafapex. All approvals are provided for 30 days to allow for an adequate time frame to administer the doses. Because of the specialized skills required for evaluation and diagnosis of patients treated with Grafapex as well as the monitoring required for adverse events and long-term efficacy, approval requires Grafapex to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Grafapex is recommended in those who meet one of the following criteria:

---

### FDA-Approved Indications

1. **Acute Myeloid Leukemia.** Approve for 30 days if the patient meets ALL of the following (A, B, C, and D):
  - A) Patient is  $\geq$  1 year of age; AND
  - B) Patient is using Grafapex in combination with fludarabine; AND
  - C) Patient is undergoing allogeneic hematopoietic stem cell transplantation; AND
  - D) The medication is prescribed by or in consultation with a hematologist, oncologist, transplant specialist physician, or a physician associated with a transplant center.
  
2. **Myelodysplastic Syndrome.** Approve for 30 days if the patient meets ALL of the following (A, B, C, and D):
  - A) Patient is  $\geq$  1 year of age; AND
  - B) Patient is using Grafapex in combination with fludarabine; AND
  - C) Patient is undergoing allogeneic hematopoietic stem cell transplantation; AND
  - D) The medication is prescribed by or in consultation with a hematologist, oncologist, transplant specialist physician, or a physician associated with a transplant center.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Grafapex is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

1. Grafapex™ intravenous infusion [prescribing information]. Chicago, IL: Medexus; January 2025.
2. The NCCN Hematopoietic Cell Transplantation (HCT) Guidelines in Oncology (version 2.2024 – August 30, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on February 22, 2025.

### HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	02/26/2025